CompoAtlas

新維礦樂軟膠囊

新維礦樂軟膠囊 : Product registered in Taiwan. This registration does not constitute authorisation for sale in France or the European Union. It does not demonstrate the safety or efficacy of the product.

TFDA, Taiwan tablets, capsules and medical nutrition registers, retrieved 27 October 2026.

Taiwan Food and Drug Administration (TFDA), Open Government Data License, version 1.0

Open Government Data License, version 1.0

The foreign register category does not determine the regulatory category of the product in France.

French and European references for recognised ingredients

Unidentified ingredients are not assessed. The absence of a signal does not establish product compliance.

Published composition

Published ingredientPublished text and quantityIdentified nutrient or substance
VITAMIN A PALMITATEVITAMIN A PALMITATENot identified
VITAMIN D3 (CHOLECALCIFEROL)VITAMIN D3 (CHOLECALCIFEROL)Vitamine D
VITAMIN E (DL-ALPHA-TOCOPHERYL ACETATE)VITAMIN E (DL-ALPHA-TOCOPHERYL ACETATE)Vitamine E
VITAMIN C (ASCORBIC ACID)VITAMIN C (ASCORBIC ACID)Vitamine C
VITAMIN B1 (THIAMINE MONONITRATE)VITAMIN B1 (THIAMINE MONONITRATE)Vitamine B1 (thiamine)
VITAMIN B2 (RIBOFLAVIN)VITAMIN B2 (RIBOFLAVIN)Vitamine B2 (riboflavine)
NICOTINAMIDENICOTINAMIDENicotinamide (vitamine B3)
VITAMIN B6 (PYRIDOXINE HYDROCHLORIDE)VITAMIN B6 (PYRIDOXINE HYDROCHLORIDE)Vitamine B6
VITAMIN B12 (CYANOCOBALAMIN)VITAMIN B12 (CYANOCOBALAMIN)Vitamine B12
CALCIUM PANTOTHENATECALCIUM PANTOTHENATEAcide pantothénique (vitamine B5)
FOLIC ACIDFOLIC ACIDFolates (vitamine B9)
BIOTINBIOTINBiotine (vitamine B8)
CHOLINE BITARTRATECHOLINE BITARTRATENot identified
DL-METHIONINEDL-METHIONINENot identified
INOSITOLINOSITOLInositol
CALCIUM PHOSPHATE, DIBASICCALCIUM PHOSPHATE, DIBASICCalcium
FERROUS FUMARATEFERROUS FUMARATEFer
MAGNESIUM SULFATEMAGNESIUM SULFATEMagnésium
ZINC GLUCONATEZINC GLUCONATEZinc
MANGANESE SULFATEMANGANESE SULFATEManganèse
POTASSIUM IODIDEPOTASSIUM IODIDEIode
COPPER GLUCONATECOPPER GLUCONATECuivre
SELENIUM YEASTSELENIUM YEASTSélénium
CHROMIUM YEASTCHROMIUM YEASTChrome
FLAX SEED OILFLAX SEED OILNot identified
PUMPKIN SEED OILPUMPKIN SEED OILNot identified
TOMATOES EXTRACT POWDERTOMATOES EXTRACT POWDERNot identified
SOYBEAN OILSOYBEAN OILNot identified
PROPOLISPROPOLISPropolis
SOY LECITHINSOY LECITHINNot identified
GELATINGELATINNot identified
GLYCEROLGLYCEROLGlycérol
PURIFIED WATERPURIFIED WATERNot identified
TITANIUM DIOXIDETITANIUM DIOXIDENot identified
BRILLIANT BLUE FCFBRILLIANT BLUE FCFNot identified
ALLURA RED ACALLURA RED ACNot identified
SUNSET YELLOW FCFSUNSET YELLOW FCFNot identified

The imported data provide no usable daily dosage. No daily dose is estimated and no comparison with dose limits is performed. A published quantity may refer to a preparation or an unspecified unit. Chinese names are retained without translation.

Product record

Registration number
1149016873
Chinese name
新維礦樂軟膠囊
English name
POLYVITA VITALON CAPSULE
Type
Imported tablets and capsules
Published status
Status not provided in this export; the validity date is shown separately
Licence holder
臺灣默化實業股份有限公司
Registration date
2025-03-28
Published validity end
2030-03-28

Original register data

View published fields and their variants
Product name
新維礦樂軟膠囊
Active ingredients
VITAMIN A PALMITATE;;VITAMIN D3 (CHOLECALCIFEROL);;VITAMIN E (DL-ALPHA-TOCOPHERYL ACETATE);;VITAMIN C (ASCORBIC ACID);;VITAMIN B1 (THIAMINE MONONITRATE);;VITAMIN B2 (RIBOFLAVIN);;NICOTINAMIDE;;VITAMIN B6 (PYRIDOXINE HYDROCHLORIDE);;VITAMIN B12 (CYANOCOBALAMIN);;CALCIUM PANTOTHENATE;;FOLIC ACID;;BIOTIN;;CHOLINE BITARTRATE;;DL-METHIONINE;;INOSITOL;;CALCIUM PHOSPHATE, DIBASIC;;FERROUS FUMARATE;;MAGNESIUM SULFATE;;ZINC GLUCONATE;;MANGANESE SULFATE;;POTASSIUM IODIDE;;COPPER GLUCONATE;;SELENIUM YEAST;;CHROMIUM YEAST;;FLAX SEED OIL;;PUMPKIN SEED OIL;;TOMATOES EXTRACT POWDER;;SOYBEAN OIL;;PROPOLIS;;SOY LECITHIN;;GELATIN;;GLYCEROL;;PURIFIED WATER;;TITANIUM DIOXIDE;;BRILLIANT BLUE FCF;;ALLURA RED AC;;SUNSET YELLOW FCF;;
Valid until
1190328
Registration number
1149016873
Licence holder
臺灣默化實業股份有限公司
Registration date
1140328
Published reference
DHC0B490168730
Published English name
POLYVITA VITALON CAPSULE

Official source

View the official register, number 1149016873

Taiwan Food and Drug Administration (TFDA), Open Government Data License, version 1.0

Open Government Data License, version 1.0

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • VITAMIN D3 (CHOLECALCIFEROL)
    Read the warning, when it applies and the studies cited

    VITAMIN D (>1,000 - 2,500 IU)

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products except products containing zinc sourced from picolinate requiring a contraindication.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have kidney disorders (NIH 2024; BfR 2020).

    Sources cited by Health Canada (2)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking other supplements or products containing vitamin D or vitamin D analogues.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking any medications including antacids, anticonvulsants, digoxin, cholestyramine, colestipol, mineral oil, steroids, statins or thiazide diuretics (NNHPD 2021; BfR 2020).

    Sources cited by Health Canada (3)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NNHPD 2021. Natural and Non-Prescription Health Products Directorate. Internal evidence and HC's product monographs.
    • DPSNSO 2021. Direction des produits de santé naturels et sans ordonnance. Preuves internes et monographies de produits internes de SC.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use to determine if you would benefit from additional vitamin D as 15-20 mcg (600-800 IU) of vitamin D per day is an adequate quantity for most individuals.

    Applies to products containing vitamin K2.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (NNHPD 2026).

    Sources cited by Health Canada (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Applies to products providing 25-34 mg of zinc per day for adults 18 years or 31-50 mg of zinc per day for adults 19 years and older.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are unsure whether you are taking enough copper as zinc supplementation can cause a copper deficiency (NNHPD 2026).

    Sources cited by Health Canada (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Contraindications

    Condition of application: All products.

    Do not use if you have hypercalcemia and/or hypercalciuria (NIH 2024; BfR 2020).

    Sources cited by Health Canada (2)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

    Applies to products containing zinc sourced from picolinate.

    Do not use if you are pregnant or breastfeeding (NNHPD 2026).

    Sources cited by Health Canada (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Known adverse reactions

    Condition of application: All products.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if the following early symptoms of hypercalcemia occur: weakness, fatigue, drowsiness, headache, lack of appetite, dry mouth, metallic taste, nausea, vomiting, vertigo, ringing in the ears, lack of coordination and muscle weakness or if you develop any other symptom (NIH 2024; BfR 2020).

    Sources cited by Health Canada (2)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

    Applies to products providing more than 350 mg of magnesium per day.

    When using this product you may experience diarrhea (NNHPD 2026).

    Sources cited by Health Canada (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Health Canada monograph dated 26 June 2026

  • PROPOLIS
    Read the warning, when it applies and the studies cited

    PROPOLIS - Oral

    Cautions and warnings

    Condition of application: All uses.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are allergic to bee products, poplar tree products, or balsam of Peru (Brinker 2010; Marcucci 1995; Valsecchi and Cainelli 1984; Melli et al. 1983; Rudzki and Gryzwa 1983).

    Sources cited by Health Canada (5)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Marcucci MC. Propolis: chemical composition, biological properties and therapeutic activity. Apidologie 1995;26:83-89.
    • Melli MC, Giorgini S, Sertoli A. Occupational dermatitis in a bee-keeper. Contact Dermatitis 1983;9(5):427-428. PubMed Case report
    • Rudzki E, Grzywa Z. Dermatitis from propolis. Contact Dermatitis 1983;9(1):40-45. PubMed
    • Valsecchi R, Cainelli T. Dermatitis from propolis. Contact Dermatitis 1984;11(5):317. PubMed

    Condition of application: Relief of sore throat/mouth and throat infections.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (PPRC 2020; Scully 2006; Hsu et al. 2004; Teraki and Shiohara 2001; Machácková 1988; Hausen et al. 1987; Valsecchi and Cainelli 1984; Melli et al. 1983; Rudzki and Grzywa 1983).

    Sources cited by Health Canada (9)
    • Hausen BM, Wollenweber E, Senff H, Post B. Propolis allergy (II): the sensitizing properties of 1,1-dimethylallyl caffeic acid ester. Contact Dermatitis 1987;17:171-177. PubMed Case report
    • Hsu CY, Chiang WC, Weng TI, Chen WJ, Yuan A. Laryngeal edema and anaphalactic shock after topical propolis use for acute pharyngitis. American Journal of Emergency Medicine 2004;22(5):432-433. PubMed Case report
    • Machackova J. The incidence of allergy to propolis in 605 consecutive patients patch tested in Prague. Contact Dermatitis 1988;18:210-212. PubMed
    • Melli MC, Giorgini S, Sertoli A. Occupational dermatitis in a bee-keeper. Contact Dermatitis 1983;9(5):427-428. PubMed Case report
    • PPRC 2020: Pharmacopoeia of the People's Republic of China, Volume 1, English edition. Beijing (CN): The State Pharmacopoeia Commission of the People's Republic of China; 2020.
    • Rudzki E, Grzywa Z. Dermatitis from propolis. Contact Dermatitis 1983;9(1):40-45. PubMed
    • Scully C. Propolis: A background (Letter). British Dental Journal 2006;200(7):359-360. PubMed
    • Teraki Y, Shiohara T. Propolis-induced granulomatous contact dermatitis accompanied by marked lymphadenopathy. British Journal of Dermatology 2001;144:1277-1278. PubMed Case report
    • Valsecchi R, Cainelli T. Dermatitis from propolis. Contact Dermatitis 1984;11(5):317. PubMed

    Health Canada monograph dated 30 May 2025

    PROPOLIS Buccal

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are allergic to bee products, poplar tree products, or balsam of Peru (Brinker 2010; Marcucci 1995; Valsecchi and Cainelli 1984; Melli et al. 1983; Rudzki and Gryzwa 1983).

    Sources cited by Health Canada (5)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Marcucci MC. Propolis: chemical composition, biological properties and therapeutic activity. Apidologie 1995;26:83-89.
    • Melli MC, Giorgini S, Sertoli A. Occupational dermatitis in a bee-keeper. Contact Dermatitis 1983;9(5):427-428. PubMed Case report
    • Rudzki E, Grzywa Z. Dermatitis from propolis. Contact Dermatitis 1983;9(1):40-45. PubMed
    • Valsecchi R, Cainelli T. Dermatitis from propolis. Contact Dermatitis 1984;11(5):317. PubMed

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: All products, except those not swallowed (e.g., gargles, rinses).

    Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you are pregnant or breastfeeding.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (PPRC 2020; Scully 2006; Hsu et al. 2004; Teraki and Shiohara 2001; Machácková 1988; Hausen et al. 1987; Valsecchi and Cainelli 1984; Melli et al. 1983; Rudzki and Grzywa 1983).

    Sources cited by Health Canada (8)
    • Hausen BM, Wollenweber E, Senff H, Post B. Propolis allergy (II): the sensitizing properties of 1,1-dimethylallyl caffeic acid ester. Contact Dermatitis 1987;17:171-177. PubMed Case report
    • Hsu CY, Chiang WC, Weng TI, Chen WJ, Yuan A. Laryngeal edema and anaphalactic shock after topical propolis use for acute pharyngitis. American Journal of Emergency Medicine 2004;22(5):432-433. PubMed Case report
    • Melli MC, Giorgini S, Sertoli A. Occupational dermatitis in a bee-keeper. Contact Dermatitis 1983;9(5):427-428. PubMed Case report
    • PPRC 2020: Pharmacopoeia of the People’s Republic of China, Volume 1, English edition. Beijing (CN): The State Pharmacopoeia Commission of the People’s Republic of China; 2020.
    • Rudzki E, Grzywa Z. Dermatitis from propolis. Contact Dermatitis 1983;9(1):40-45. PubMed
    • Scully C. Propolis: A background (Letter). British Dental Journal 2006;200(7):359-360. PubMed
    • Teraki Y, Shiohara T. Propolis-induced granulomatous contact dermatitis accompanied by marked lymphadenopathy. British Journal of Dermatology 2001;144:1277-1278. PubMed Case report
    • Valsecchi R, Cainelli T. Dermatitis from propolis. Contact Dermatitis 1984;11(5):317. PubMed

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 29 May 2026

They concern the ingredient, not this product or its dose. They do not replace medical advice.

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line